Hanmi Pharmaceutical, approximately 2 trillion won technology export disclosure, target price raised to 71 ten thousand won

Hana Securities raised Hanmi Pharmaceutical's target price on 6 from the previous 8 ten thousand won to 64 ten thousand won. Hana Securities said the adjustment was based on its report. The report cited a revaluation of pipeline value and expectations of additional technology exports as reasons for the increase.71 ten thousand won

Hanmi Pharmaceutical announced in a disclosure on 6 that it had signed a technology export contract worth approximately 1 trillion won. The disclosure stated that the technology export had taken place. The company disclosed the contract through the announcement.2 trillion won

Hana Securities wrote in its report that it had revalued the pipeline's worth to reflect the contents of the disclosure. The report also mentioned the possibility of additional technology exports. Hana Securities presented these points as the basis for raising its target price.

Hanmi Pharmaceutical’s disclosure and Hana Securities’ report were each issued in the form of a disclosure and a report, respectively. The two documents stated that they addressed the same matter. Disclosures and reports are official documents that investors can review.

Hanmi Pharmaceutical and Hana Securities each announced the news through a disclosure and a report, respectively. Investors can review the original disclosure and the securities firm’s report. The relevant documents can be found in the electronic disclosure system and the securities firm’s reports.